Clinical trials: Carcinoma Breast
Breast Cancer, Autoimmune Disease
Continuation of Follow-up of DES-Exposed Cohorts
Diethylstilbestrol (DES), a drug first synthesized in 1938, was administered to several million pregnant women in the U.S. and Europe for the prevention of spontaneous abortion and premature delivery.
- Conditions
- Breast Cancer, Autoimmune Disease, Prostate Cancer, Ovarian Cancer
- Trial name
- NCT00340600
- Where
- United States
- Volunteers
- 10,805 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
Combination Chemotherapy Before Surgery in Treating Women With Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells and shrink tumors so they can be removed during…
- Trial name
- NCT00008034
- Testing
- capecitabine, cyclophosphamide, epirubicin hydrochloride
- Where
- Switzerland
- Volunteers
- 15 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Breast Cancer
Efficacy and Safety of Inetetamab Plus Pyrotiniband and Capecitabine in HER2-positive Metastatic Breast Cancer Patients With or Without Brain Metastasis
This study intends to include HER2-positive metastatic breast cancer patients (with or without brain metastasis) who have become resistant to previous treatment with trastuzumab.
- Trial name
- NCT06015100
- Testing
- Inetetamab plus pyrotiniband and capecitabine
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Yan Xue
Breast Cancer, Colon Cancer
The Efficacy of Health Partnership Program for Cancer Patients
The Objectives of this study is 1. To evaluate the efficacy for exercise, diet, and posttraumatic growth as a result of participating in tailored program (Health Partnership Program) for 24 weeks 2.
- Conditions
- Breast Cancer, Colon Cancer, Gastric Cancer, Lung Cancer
- Trial name
- NCT01527409
- Testing
- Tailored health partnership program, Usual care and health education workshop
- Where
- 10 sites in South Korea
- Volunteers
- 248 people, healthy volunteers welcome
- Sponsor
- National Cancer Center, Korea
Breast Cancer
Multiparametric High-resolution Ultrasound of the Breast
Despite advances in mammographic technique, mammography is limited in the detection and diagnosis of breast lesions with respect to sensitivity and specificity.
- Trial name
- NCT03276845
- Testing
- Ultrasound of the breast
- Volunteers
- 124 people
- Sponsor
- Medical University of Vienna
Advanced Breast Cancer
HDAC Inhibitor Vorinostat (SAHA) With Capecitabine (Xeloda) Using a New Weekly Dose Regimen for Advanced Breast Cancer
The purpose of this study is to determine the safety profile, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), of oral vorinostat in combination with oral capecitabine given on days 1-7 and 15-21 of a 28 day cycle in…
- Trial name
- NCT00719875
- Testing
- Vorinostat
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Yale University
Breast Cancer
Development of Gourmet Healthy Cooking Workshop for Cancer Patients
Subjects that participate in the practical workshop will improve their metabolic indexes, control their weight and improve their quality of life, in contrast to the participants that will take part in the nutritional consulting…
- Trial name
- NCT00364975
- Testing
- gourmet cooking workshop
- Where
- Israel
- Sponsor
- Hadassah Medical Organization
Breast Cancer, Postoperative Pain
Liposomal Bupivacaine in Implant Based Breast Reconstruction
Objectives: 1. To evaluate the effect of liposomal bupivacaine on postoperative pain levels. 2. To evaluate the effect of liposomal bupivacaine on postoperative opioid consumption and opioid related adverse events. 3.
- Trial name
- NCT02659501
- Testing
- Liposomal bupivacaine, Bupivacaine with epinephrine, Morphine sulfate
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Loma Linda University
Breast Cancer
Delayed-Delayed Breast Reconstruction
The goal of this clinical research study is to learn if delayed-delayed breast reconstruction in women who require post-mastectomy radiation therapy will improve cosmetic outcomes and result in fewer complications compared to the…
- Trial name
- NCT01256528
- Testing
- Delayed Breast Reconstruction
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- M.D. Anderson Cancer Center
Multiple Myeloma, Triple Negative Breast Cancer
Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype
This study is comprised of a main study, an observational study, and optional survey studies. The main study is being done to see whether using Duffy null specific treatment dosing guidelines can reduce or delay dose…
- Conditions
- Multiple Myeloma, Triple Negative Breast Cancer, Duffy Blood Group, Chemokine Receptor Gene Mutation, Duffy Blood Group, Chemokine Receptor Gene C.-67T>C
- Trial name
- NCT07341867
- Testing
- Dexamethasone, Bortezomib, LENALIDOMIDE
- Where
- 2 sites in United States
- Volunteers
- 90 people
- Sponsor
- Andrew Hantel, MD
Breast Cancer
6 FEC 100 Vs 4 FEC 100 Followed by 4 Taxol in N+ Breast Cancer
The main objective of this randomized trial is to compare 6 FEC100 to 4 FEC100 + 4 Taxol in patients with resected node positive breast cancer. Main endpoint is disease free survival.
- Trial name
- NCT00189644
- Testing
- 6 FEC 100, 4 FEC 100 followed by 4 Taxol
- Sponsor
- Association Européenne de Recherche en Oncologie
Atypical Ductal Breast Hyperplasia, Lobular Carcinoma in Situ (LCIS)
Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor: A Proof of Principle Trial
Atypical ductal hyperplasia (ADH) and atypical lobular hyperplasia (ALH) increases breast cancer risk. In post menopausal women, SERMS are standard chemopreventive agents.
- Conditions
- Atypical Ductal Breast Hyperplasia, Lobular Carcinoma in Situ (LCIS), Atypical Lobular Hyperplasia (ALH) of Breast
- Trial name
- NCT01372644
- Testing
- SOM 230 / Pasireotide
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Breast Neoplasms
A Study to Evaluate Denosumab in Young Patients With Primary Breast Cancer
This is a prospective, single arm phase IIa trial in which patients with early breast cancer will receive pre-operatively two doses of denosumab 120mg subcutaneously one week apart (maximum 12 days) followed by surgery.
- Trial name
- D-Beyond (NCT01864798)
- Testing
- Denosumab
- Where
- 6 sites in Australia, Belgium
- Volunteers
- 27 people
- Sponsor
- Jules Bordet Institute
Breast Cancer, Heart Failure
CardioPROTECTion with Dapagliflozin in Breast Cancer Patients Treated with AnthrAcycline - PROTECTAA TRIAL
The purpose of this study is to evaluate the effect of dapagliflozin on the incidence of cancer therapeutics-related cardiac dysfunction in patients with breast cancer receiving anthracycline treatment.
- Trial name
- PROTECTAA (NCT06304857)
- Testing
- Dapagliflozin
- Where
- 3 sites in Poland
- Volunteers
- 188 people
- Sponsor
- 4th Military Clinical Hospital with Polyclinic, Poland
Breast Cancer, Iron Chelation
Ketotifen: as a Cardioprotective Agent in Breast Cancer Patients Receiving Anthracycline-containing Chemotherapy
The objective of our study was to evaluate the expected cardioprotective effects of ketotifen due to its activity as an iron-chelating agent previously uncovered by us in the in vitro chemical test which included in the study…
- Trial name
- NCT04435028
- Testing
- Ketotifen 1 MG
- Where
- Egypt
- Volunteers
- 111 people
- Sponsor
- Horus University
Breast Cancer, Advanced Solid Tumor
An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-75202 (KAT6A/B inhibitor) alone and in combination with other therapies in…
- Trial name
- NCT07222267
- Testing
- BG-75202, CDK4 Inhibitor, Estrogen Receptor Antagonist
- Where
- 32 sites in United States, Australia and 4 more
- Volunteers
- 86 people
- Sponsor
- BeOne Medicines
Breast Cancer
Trial of RAD001 in Triple Negative Metastatic Breast Cancer
The hypothesis of this clinical research study is to discover if the study drug RAD001 can shrink or slow the growth of Estrogen Receptor/Progesterone Receptor (ER/PR) negative or Human Epidermal growth factor Receptor 2 (Her2…
- Trial name
- NCT00827567
- Testing
- RAD 001
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Milton S. Hershey Medical Center
Breast Cancer, Image Guided Biopsy
In Vivo Smart Biopsy Device Protocol In Radiology
This study is designed to demonstrate the feasibility of use of the Smart Biopsy Device in real clinical settings.
- Trial name
- NCT03914911
- Testing
- Smart Biopsy Device
- Where
- 2 sites in Israel
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Dune Medical Devices
HER2-negative Breast Cancer
Eribulin Combined With Anlotinib in Metastatic HER2 Negative Breast Cancer
This is a multicenter, phase II, open-label, single-arm investigator initiated trial to evaluate the efficacy and safety of eribulin mesylate combined with anlotinib in metastatic HER2 negative breast cancer patients.
- Trial name
- NCT04624711
- Testing
- Eribulin Mesylate, Anlotinib hydrochloride
- Where
- China
- Volunteers
- 40 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Breast Cancer
Autotaxin: a Potential Biomarker for Breast Cancer.
The goal of this clinical trial is to test the efficiency of Autotaxin (ATX) as a biomarker for breast cancer patients. The main questions it aims to answer are; is ATX a reliable tumor marker for breast cancer patients in…
- Trial name
- NCT05680311
- Testing
- measurement of serum autotaxin serum level
- Where
- Turkey (Türkiye)
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Ankara Etlik City Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.